Nuklearmedizin 2019; 58(02): 124
DOI: 10.1055/s-0039-1683525
Vorträge
PET: FDG und neue Tracer
Georg Thieme Verlag KG Stuttgart · New York

68Ga-NODAGA-exendin-4 PET/CT for the localization of insulinomas

M Boss
1   Radboudumc, Nuclear Medicine, Nijmegen
,
K Mikkola
2   University of Turku, Turku PET Centre, Turku
,
M Buitinga
3   Radboudumc, Nijmegen
,
M Brom
3   Radboudumc, Nijmegen
,
D Wild
4   University of Basel Hospital, Basel
,
V Prasad
5   Charité University Hospital of Berlin, Berlin
,
A Brouwers
6   University Medical Center Groningen, Groningen
,
F Pattou
7   University Hospital, Lille, Lille
,
P Nuutila
2   University of Turku, Turku PET Centre, Turku
,
M Gotthardt
3   Radboudumc, Nijmegen
› Author Affiliations
Further Information

Publication History

Publication Date:
27 March 2019 (online)

 

Ziel/Aim:

Insulinomas are usually small, single benign tumors. Precise preoperative anatomical localization of the tumor is essential. Imaging techniques like CT, MRI as well as somatostatin receptor (SSTR) imaging have limited sensitivity (1). The stable glucagon like peptide-1 (GLP-1) analog exendin specifically binds the GLP-1 receptor (GLP-1R), which is markedly overexpressed in insulinomas. We propose 68Ga-NODAGA-exendin-4 PET/CT as a promising new method for improved localization of insulinomas.

Methodik/Methods:

44 adults aged 24 – 65 with biochemically proven hyperinsulinemic hypoglycemia were included. PET/CT images were obtained one and two hours after injection of (5 – 7 µg) 95 – 105 MBq 68Ga-NODAGA-exendin-4. Current standard imaging was performed within 8 weeks of 68Ga-NODAGA-exendin-PET in all patients, consisting of CT or MRI and SSTR PET imaging.

Ergebnisse/Results:

In 34 of the patients a focus was identified with one or more of the imaging techniques. Of these patients, 29 have undergone surgery so far and in these patients 34 insulinoma have been removed and pathologically confirmed to be insulin positive tumors. 68Ga-NODAGA-exendin-4 PET imaging detected these insulinomas with a sensitivity of 85.3%. Sst-receptor PET and conventional imaging had a sensitivity of 54.5% and 66.7% respectively for detection of these insulinomas. Image quality of 68Ga-NODAGA-exendin-4 PET imaging was better than Sst-receptor PET.

Schlussfolgerungen/Conclusions:

In conclusion, 68Ga-NODAGA-exendin-4 PET/CT performed better than standard imaging methods, which indicated it is a promising new technique for non-invasive pre-operative detection of insulinomas.

Literatur/References:

[1] Nockel P, Babic B, Millo C, Herscovitch P, Patel D, Nilubol N, et al. Localization of Insulinoma Using 68Ga-DOTATATE PET/CT Scan. The Journal of clinical endocrinology and metabolism. 2017;102(1):195 – 9.